Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.5/5.0
Behavior4/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already indicate read-only, idempotent, non-destructive behavior. The description adds valuable context: data sources (SEC EDGAR/XBRL for companies, FAERS for drugs), handling of off-calendar fiscal years, sorting by primary metric, and inclusion of citation URIs. It does not contradict the annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is moderately long but dense with useful information, starting with example triggers. Each sentence contributes to understanding, though it could be slightly more concise. Overall well-structured for an AI agent.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the absence of an output schema, the description adequately explains return values (paired data + citation URIs) and sorting. Combined with comprehensive annotations and schema, the description is near-complete for effective tool invocation.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so baseline is 3. The description adds meaning beyond the schema by explaining what each enum value retrieves (company: revenue, net income, cash, debt; drug: FAERS counts, FDA approvals, trial counts) and the format for values (tickers/CIKs for companies, names for drugs). This enhances parameter understanding.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool performs side-by-side comparisons of 2-5 companies or drugs, using specific verbs like 'compare', 'versus', 'rank'. It distinguishes itself from sequential single-entity lookups, making the purpose unmistakable.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly instructs 'ALWAYS PREFER over sequential single-pack lookups when comparing entities' and provides trigger phrases like 'compare X and Y', 'which is bigger', 'rank these companies'. This gives strong guidance on when to use the tool.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4/5.0
Disambiguation4/5

Most tools have clearly distinct purposes, but several overlap heavily: ask_pipeworx, ask_pipeworx_beta, and ask_pipeworx_grounded are near-identical (only differing in verification/depth), and polymarket_edges / polymarket_arbitrage / polymarket_edge_tracker / polymarket_fill_risk / polymarket_kalshi_spread all target similar prediction-market signals, which could cause mis-selection without careful reading.

Naming Consistency4/5

Most names follow a clear verb_noun pattern (resolve_entity, query_table, remember, recall, forget, subscribe, unsubscribe, validate_claim, compare_entities, search_within), but there are exceptions like ai_visibility_check (adjective_noun), generate_llms_txt (verb_noun with dot), and several polymarket_* names that are fine but inconsistent with the snake_case verb-first convention.

Tool Count5/5

35 tools is a large but reasonable surface for a broad data/serach platform covering company financials, economics, prediction markets, memory, subscriptions, and discovery. The count is justified by the wide domain, and the set is not bloated with trivial duplicates.

Completeness4/5

The surface covers core CRUD for entities (resolve, profile, compare, search, query) and memory (remember/recall/forget), plus subscriptions and meta-tools. Minor gaps: no explicit tool for updating/creating entities (understandable for a read-only data service), and no tool for listing all available table schemas beyond discovery (subjects covers this). Overall strong coverage.